Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI), Kadmon Holdings (KDMN) and Endo International (ENDP).
Cigna (CI)
In a report released today, John Ransom from Raymond James reiterated a Buy rating on Cigna, with a price target of $317.00. The company’s shares closed last Friday at $261.18, close to its 52-week high of $263.67.
According to TipRanks.com, Ransom is a 5-star analyst with an average return of 15.5% and a 65.4% success rate. Ransom covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Acadia Healthcare, and Oak Street Health.
Cigna has an analyst consensus of Strong Buy, with a price target consensus of $280.17, which is a 9.0% upside from current levels. In a report issued on April 26, Wolfe Research also maintained a Buy rating on the stock with a $294.00 price target.
See today’s analyst top recommended stocks >>
Kadmon Holdings (KDMN)
In a report issued on May 7, Steven Seedhouse from Raymond James maintained a Buy rating on Kadmon Holdings, with a price target of $10.00. The company’s shares closed last Friday at $3.79.
According to TipRanks.com, Seedhouse is a 3-star analyst with an average return of 3.6% and a 41.1% success rate. Seedhouse covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Apellis Pharmaceuticals, and Alexion Pharmaceuticals.
Currently, the analyst consensus on Kadmon Holdings is a Strong Buy with an average price target of $12.75, which is a 244.6% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.
Endo International (ENDP)
In a report released yesterday, Elliot Wilbur from Raymond James maintained a Hold rating on Endo International. The company’s shares closed last Friday at $5.63.
According to TipRanks.com, Wilbur is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -3.5% and a 41.3% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on Endo International is a Hold with an average price target of $8.38.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
